537 related articles for article (PubMed ID: 33547249)
41. Development of a miniaturized 3D organoid culture platform for ultra-high-throughput screening.
Du Y; Li X; Niu Q; Mo X; Qui M; Ma T; Kuo CJ; Fu H
J Mol Cell Biol; 2020 Aug; 12(8):630-643. PubMed ID: 32678871
[TBL] [Abstract][Full Text] [Related]
42. Automation of Organoid Cultures: Current Protocols and Applications.
Louey A; Hernández D; Pébay A; Daniszewski M
SLAS Discov; 2021 Oct; 26(9):1138-1147. PubMed ID: 34167363
[TBL] [Abstract][Full Text] [Related]
43. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.
Haggarty SJ; Silva MC; Cross A; Brandon NJ; Perlis RH
Mol Cell Neurosci; 2016 Jun; 73():104-15. PubMed ID: 26826498
[TBL] [Abstract][Full Text] [Related]
44. Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons.
Engle SJ; Blaha L; Kleiman RJ
Neuron; 2018 Nov; 100(4):783-797. PubMed ID: 30465765
[TBL] [Abstract][Full Text] [Related]
45. Humanized brain organoids-on-chip integrated with sensors for screening neuronal activity and neurotoxicity.
Saglam-Metiner P; Yildirim E; Dincer C; Basak O; Yesil-Celiktas O
Mikrochim Acta; 2024 Jan; 191(1):71. PubMed ID: 38168828
[TBL] [Abstract][Full Text] [Related]
46. Organoid technology in female reproductive biomedicine.
Heidari-Khoei H; Esfandiari F; Hajari MA; Ghorbaninejad Z; Piryaei A; Baharvand H
Reprod Biol Endocrinol; 2020 Jun; 18(1):64. PubMed ID: 32552764
[TBL] [Abstract][Full Text] [Related]
47. Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments.
McGivern JV; Ebert AD
Adv Drug Deliv Rev; 2014 Apr; 69-70():170-8. PubMed ID: 24309014
[TBL] [Abstract][Full Text] [Related]
48. A CRISP(e)R view on kidney organoids allows generation of an induced pluripotent stem cell-derived kidney model for drug discovery.
Boreström C; Jonebring A; Guo J; Palmgren H; Cederblad L; Forslöw A; Svensson A; Söderberg M; Reznichenko A; Nyström J; Patrakka J; Hicks R; Maresca M; Valastro B; Collén A
Kidney Int; 2018 Dec; 94(6):1099-1110. PubMed ID: 30072040
[TBL] [Abstract][Full Text] [Related]
49. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments.
Astashkina A; Grainger DW
Adv Drug Deliv Rev; 2014 Apr; 69-70():1-18. PubMed ID: 24613390
[TBL] [Abstract][Full Text] [Related]
50. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors.
Zhang YS; Aleman J; Shin SR; Kilic T; Kim D; Mousavi Shaegh SA; Massa S; Riahi R; Chae S; Hu N; Avci H; Zhang W; Silvestri A; Sanati Nezhad A; Manbohi A; De Ferrari F; Polini A; Calzone G; Shaikh N; Alerasool P; Budina E; Kang J; Bhise N; Ribas J; Pourmand A; Skardal A; Shupe T; Bishop CE; Dokmeci MR; Atala A; Khademhosseini A
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):E2293-E2302. PubMed ID: 28265064
[TBL] [Abstract][Full Text] [Related]
51. Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models.
Logan S; Arzua T; Canfield SG; Seminary ER; Sison SL; Ebert AD; Bai X
Compr Physiol; 2019 Mar; 9(2):565-611. PubMed ID: 30873582
[TBL] [Abstract][Full Text] [Related]
52. Development of high-throughput lacrimal gland organoid platforms for drug discovery in dry eye disease.
Rodboon T; Yodmuang S; Chaisuparat R; Ferreira JN
SLAS Discov; 2022 Apr; 27(3):151-158. PubMed ID: 35058190
[TBL] [Abstract][Full Text] [Related]
53. A Simple Procedure for Creating Scalable Phenotypic Screening Assays in Human Neurons.
Sridharan B; Hubbs C; Llamosas N; Kilinc M; Singhera FU; Willems E; Piper DR; Scampavia L; Rumbaugh G; Spicer TP
Sci Rep; 2019 Jun; 9(1):9000. PubMed ID: 31227747
[TBL] [Abstract][Full Text] [Related]
54. Impact of new technologies for cellular screening along the drug value chain.
Möller C; Slack M
Drug Discov Today; 2010 May; 15(9-10):384-90. PubMed ID: 20206290
[TBL] [Abstract][Full Text] [Related]
55. Pluripotent stem cells for neurodegenerative disease modeling: an expert view on their value to drug discovery.
Chen SD; Li HQ; Cui M; Dong Q; Yu JT
Expert Opin Drug Discov; 2020 Sep; 15(9):1081-1094. PubMed ID: 32425128
[TBL] [Abstract][Full Text] [Related]
56. High-throughput screening in primary neurons.
Sharma P; Ando DM; Daub A; Kaye JA; Finkbeiner S
Methods Enzymol; 2012; 506():331-60. PubMed ID: 22341232
[TBL] [Abstract][Full Text] [Related]
57. Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling.
Skardal A; Shupe T; Atala A
Drug Discov Today; 2016 Sep; 21(9):1399-1411. PubMed ID: 27422270
[TBL] [Abstract][Full Text] [Related]
58. Filling the drug discovery gap: is high-content screening the missing link?
Dorval T; Chanrion B; Cattin ME; Stephan JP
Curr Opin Pharmacol; 2018 Oct; 42():40-45. PubMed ID: 30032033
[TBL] [Abstract][Full Text] [Related]
59. Emerging three-dimensional neuronal culture assays for neurotherapeutics drug discovery.
Rathore RS; R Ayyannan S; Mahto SK
Expert Opin Drug Discov; 2022 Jun; 17(6):619-628. PubMed ID: 35373682
[TBL] [Abstract][Full Text] [Related]
60. Screening methods for influenza antiviral drug discovery.
Atkins C; Evans CW; White EL; Noah JW
Expert Opin Drug Discov; 2012 May; 7(5):429-38. PubMed ID: 22435452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
